Network Point of Care Glucose Testing Market-Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032
Description
Market Overview
The global Network POC glucose testing market is projected to grow from USD 1,105 million in 2024 to USD 2,620.85 million by 2032, reflecting a CAGR of 11.4%.
This growth is driven by rising demand for efficient diabetes management solutions and technological advancements in medical diagnostics. The increasing prevalence of diabetes, along with the growing need for real-time monitoring and faster diagnosis, is expected to further bolster market growth. Key trends include wireless connectivity in glucose meters, cloud-based platforms for data sharing, and the growing focus on healthcare digitization and remote monitoring solutions.
Market Drivers
Increasing Prevalence of Diabetes
The global rise in diabetes cases is a primary driver for the market. For instance, the International Diabetes Federation reported that the number of adults living with diabetes in North America reached 50 million in 2023. This growing patient population increases demand for advanced POC glucose testing systems, as early detection and continuous monitoring are crucial for preventing complications and improving disease management.
Market Challenges
High Cost of Advanced Devices
The high cost of advanced testing devices is a significant barrier. While these systems offer real-time monitoring and seamless integration with digital platforms, their purchase price can be prohibitive, especially for healthcare facilities in emerging economies. This restricts widespread adoption, limiting availability to well-funded healthcare providers and slowing broader market growth.
Segmentations
By Product Type:
Blood-Glucose Meter
Lancing Devices and Strips
By Application:
Type-1 Diabetes
Type-2 Diabetes
By End-User:
Home Care Settings
Hospitals and Clinics
Others
By Region:
North America: U.S., Canada, Mexico
Europe: UK, France, Germany, Italy, Spain, Russia, Belgium, Netherlands, Austria, Sweden, Poland, Denmark, Switzerland, Rest of Europe
Asia Pacific: China, Japan, South Korea, India, Australia, Thailand, Indonesia, Vietnam, Malaysia, Philippines, Taiwan, Rest of APAC
Latin America: Brazil, Argentina, Peru, Chile, Colombia, Rest of Latin America
Middle East: UAE, KSA, Israel, Turkey, Iran, Rest of Middle East
Africa: Egypt, Nigeria, Algeria, Morocco, Rest of Africa
Key Players:
Nova Biomedical Corporation
Nipro
ACON Laboratories, Inc.
Trividia Health, Inc.
Platinum Equity Advisors LLC
Prodigy Diabetes Care LLC
Hoffmann-La Roche Ltd
EKF Diagnostics Holdings plc
Abbott Laboratories
Ascensia Diabetes Care Holdings AG
The global Network POC glucose testing market is projected to grow from USD 1,105 million in 2024 to USD 2,620.85 million by 2032, reflecting a CAGR of 11.4%.
This growth is driven by rising demand for efficient diabetes management solutions and technological advancements in medical diagnostics. The increasing prevalence of diabetes, along with the growing need for real-time monitoring and faster diagnosis, is expected to further bolster market growth. Key trends include wireless connectivity in glucose meters, cloud-based platforms for data sharing, and the growing focus on healthcare digitization and remote monitoring solutions.
Market Drivers
Increasing Prevalence of Diabetes
The global rise in diabetes cases is a primary driver for the market. For instance, the International Diabetes Federation reported that the number of adults living with diabetes in North America reached 50 million in 2023. This growing patient population increases demand for advanced POC glucose testing systems, as early detection and continuous monitoring are crucial for preventing complications and improving disease management.
Market Challenges
High Cost of Advanced Devices
The high cost of advanced testing devices is a significant barrier. While these systems offer real-time monitoring and seamless integration with digital platforms, their purchase price can be prohibitive, especially for healthcare facilities in emerging economies. This restricts widespread adoption, limiting availability to well-funded healthcare providers and slowing broader market growth.
Segmentations
By Product Type:
Blood-Glucose Meter
Lancing Devices and Strips
By Application:
Type-1 Diabetes
Type-2 Diabetes
By End-User:
Home Care Settings
Hospitals and Clinics
Others
By Region:
North America: U.S., Canada, Mexico
Europe: UK, France, Germany, Italy, Spain, Russia, Belgium, Netherlands, Austria, Sweden, Poland, Denmark, Switzerland, Rest of Europe
Asia Pacific: China, Japan, South Korea, India, Australia, Thailand, Indonesia, Vietnam, Malaysia, Philippines, Taiwan, Rest of APAC
Latin America: Brazil, Argentina, Peru, Chile, Colombia, Rest of Latin America
Middle East: UAE, KSA, Israel, Turkey, Iran, Rest of Middle East
Africa: Egypt, Nigeria, Algeria, Morocco, Rest of Africa
Key Players:
Nova Biomedical Corporation
Nipro
ACON Laboratories, Inc.
Trividia Health, Inc.
Platinum Equity Advisors LLC
Prodigy Diabetes Care LLC
Hoffmann-La Roche Ltd
EKF Diagnostics Holdings plc
Abbott Laboratories
Ascensia Diabetes Care Holdings AG
Table of Contents
220 Pages
- 1. Executive Summary
- Market Overview
- Key Findings
- Market Trends and Insights
- 2. Market Introduction
- Definition of Network Point of Care Glucose Testing
- Market Scope
- Key Market Drivers and Challenges
- Market Restraints and Opportunities
- 3. Market Segmentation
- 3.1 By Product Type
- Glucose Meters
- Test Strips
- Continuous Glucose Monitoring Devices
- Other Products
- 3.2 By Application
- Hospitals & Clinics
- Diagnostic Centers
- Home Healthcare
- Others
- 3.3 By End-User
- Hospitals
- Ambulatory Care Centers
- Home Users
- Others
- 3.4 By Region
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
- 4. Competitive Landscape
- Market Share Analysis
- Strategic Initiatives
- Mergers & Acquisitions
- 5. Key Player Analysis
- Nova Biomedical Corporation
- Nipro
- ACON Laboratories, Inc.
- Trividia Health, Inc.
- Platinum Equity Advisors LLC
- Prodigy Diabetes Care LLC
- Hoffmann-La Roche Ltd
- EKF Diagnostics Holdings plc.
- Abbott Laboratories
- Ascensia Diabetes Care Holdings AG
- 6. Market Forecast (2024–2032)
- By Product Type
- By Application
- By End-User
- By Region
- 7. Conclusion & Recommendations
- Strategic Recommendations
- Market Outlook
- 8. Appendix
- Methodology
- Data Sources
- Abbreviations
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.